Schleifer was the top pick of TheStreet readers for his execution of one of the most successful new drug launches in history. Eylea was approved in November 2011 to treat a common cause of blindness. In just nine months, Eylea sales have already reached $562 million with an annual run rate close to $1 billion, well above the company's -- and investors' -- initial forecasts.
Well done, Len!
Schleifer wins the 2012 Best Biotech CEO Award with 37% of 1,121 votes cast. For his victory, Schleifer takes home the Swanson Trophy, named in honor of Robert Swanson, Genentech's founding CEO.The runner-up this year was Onyx Pharmaceuticals' (ONXX) Tony Coles with 28% of votes cast. With two new cancer drug approvals in 2012, Coles had a stellar year. Right behind Coles in third place, just six votes short, was Chris Garabedian of Sarepta Therapeutics (SRPT - Get Report). In fourth place: Gilead Sciences' (GILD - Get Report) John Martin. Congratulation to all of this year's Best Biotech CEO nominees, and thanks to everyone who participated in the voting process. -- Reported by Adam Feuerstein in Boston. Follow @AdamFeuerstein